{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-25-000062","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.851034+00:00","generated_at":"2026-05-21T15:57:26.717586+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acumen Pharma Q1 net loss $28.8M; Phase 2 Alzheimer's trial fully enrolled, results late 2026","bullets":["Net loss $28.8M in Q1 2025 ($14.9M Q1 2024); loss from operations $30.4M vs $17.8M.","R&D expenses $25.3M (up 104% YoY) driven by ALTITUDE-AD Phase 2 clinical trial costs.","Cash, cash equivalents and marketable securities $197.9M, expected to fund operations into early 2027.","Phase 2 ALTITUDE-AD study of sabirnetug fully enrolled (542 participants); topline data readout late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-25-000062","json":"https://secwatch.observer/filing/0001576885-25-000062.json","markdown":"https://secwatch.observer/filing/0001576885-25-000062.md","text":"https://secwatch.observer/filing/0001576885-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/0001576885-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/abos-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:57:26.717586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}